methenamine hippurate UTI
Selected indexed studies
- Methenamine Hippurate in UTI management: a reemerging pharmacological strategy. (Expert Rev Clin Pharmacol, 2024) [PMID:39699112]
- Guideline of guidelines: management of recurrent urinary tract infections in women. (BJU Int, 2022) [PMID:35579121]
- Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women-a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU). (Clin Microbiol Infect, 2025) [PMID:40669691]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women-a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU). (2025) pubmed
- Methenamine hippurate for preventing urinary tract infections. (2012) pubmed
- Methenamine hippurate for preventing urinary tract infections. (2007) pubmed
- Methenamine hippurate for preventing urinary tract infections. (2002) pubmed
- Methenamine Hippurate in UTI management: a reemerging pharmacological strategy. (2024) pubmed
- Guideline of guidelines: management of recurrent urinary tract infections in women. (2022) pubmed
- Acute Uncomplicated UTIs in Adults: Rapid Evidence Review. (2024) pubmed
- Nonantibiotic prevention and management of recurrent urinary tract infection. (2018) pubmed
- The resurgence of methenamine hippurate in the prevention of recurrent UTIs in women- a systematic review. (2023) pubmed
- Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis. (2021) pubmed